Last reviewed · How we verify
sitagliptin and acarbose
This combination reduces blood glucose by inhibiting dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and slowing carbohydrate digestion via alpha-glucosidase inhibition.
This combination reduces blood glucose by inhibiting dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and slowing carbohydrate digestion via alpha-glucosidase inhibition. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | sitagliptin and acarbose |
|---|---|
| Sponsor | Nanjing First Hospital, Nanjing Medical University |
| Drug class | DPP-4 inhibitor + alpha-glucosidase inhibitor combination |
| Target | DPP-4 enzyme; alpha-glucosidase enzymes |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Sitagliptin is a DPP-4 inhibitor that prolongs the action of incretin hormones (GLP-1 and GIP), which stimulate insulin secretion in response to meals. Acarbose is an alpha-glucosidase inhibitor that delays carbohydrate breakdown and absorption in the small intestine, reducing postprandial glucose spikes. Together, they provide complementary mechanisms to lower blood glucose in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Gastrointestinal disturbances (diarrhea, flatulence, abdominal discomfort)
- Hypoglycemia
- Headache
- Nasopharyngitis
Key clinical trials
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- Comparison of the FGM Profiles in Patients of Type 2 Diabetes Treated With Sitagliptin and Acarbose (NA)
- Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients (PHASE4)
- A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) (PHASE4)
- A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313) (PHASE4)
- Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130) (PHASE3)
- Treatment of Hypoglycemia Following Gastric Bypass Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sitagliptin and acarbose CI brief — competitive landscape report
- sitagliptin and acarbose updates RSS · CI watch RSS
- Nanjing First Hospital, Nanjing Medical University portfolio CI